Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Liver disease

Writing and erasing ceramides to alter liver disease

M6A RNA modifications mediate RNA processing and stability. Ceramides are lipid metabolites containing an amino acid-based backbone, which promote metabolic dysfunction. Wang et al. describe a novel m6A-dependent regulatory node that tunes ceramide-generating enzymes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: By altering the stability of mRNA transcripts, Mettl3–m6A alters sphingolipid metabolism.

References

  1. Summers, S. A., Chaurasia, B. & Holland, W. L. Nat. Metab. 1, 1051–1058 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hilvo, M., Vasile, V. C., Donato, L. J., Hurme, R. & Laaksonen, R. Front. Endocrinol. (Lausanne) 11, 570628 (2020).

    Article  PubMed  Google Scholar 

  3. Wang, S. Nat. Metab. https://doi.org/10.1038/s42255-023-00808-9 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. He, P. C. & He, C. EMBO J. 40, e105977 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jia, G. et al. Nat. Chem. Biol. 7, 885–887 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chaurasia, B. & Summers, S. A. Annu. Rev. Physiol. 83, 303–330 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Chaurasia, B. et al. Science 365, 386–392 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hammerschmidt, P. et al. Cell 177, 1536–1552.e23 (2019).

    Article  CAS  PubMed  Google Scholar 

  9. Raichur, S. et al. Cell Metab. 20, 687–695 (2014).

    Article  CAS  PubMed  Google Scholar 

  10. Xu, Y. et al. Nat. Commun. 13, 4555 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Turpin, S. M. et al. Cell Metab. 20, 678–686 (2014).

    Article  CAS  PubMed  Google Scholar 

  12. Li, X. et al. Nat. Commun. 12, 7213 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors received research support from the National Institutes of Health (DK115824, DK116888, and DK116450 to SAS; DK112826 and DK130296 to WLH), the American Diabetes Association (to WLH), the Margolis Foundation (to WLH).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William L. Holland.

Ethics declarations

Competing interests

S.A.S. is a consultant, co-founder and shareholder in Centaurus Therapeutics, LLC. All other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weber-Stout, M., Summers, S.A. & Holland, W.L. Writing and erasing ceramides to alter liver disease. Nat Metab 5, 727–729 (2023). https://doi.org/10.1038/s42255-023-00809-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-023-00809-8

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing